Biased Ligands. Better Drugs.

TRV027 Publications

Article - BLAST-AHF trial design

Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor : Rationale and Design of the BLAST-AHF Study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail. 2015 Mar;3(3):193-201. doi: 10.1016/j.jchf.2014.09.008. Epub 2015 Jan 28.

Poster - TRV027 Phase 2b trial design

Rationale and Design of the TRV027 Biased Ligand at the Angiotensin Receptor Study in Acute Heart Failure (BLAST-AHF). Presented at the 2014 European Society for Cardiology – Heart Failure meeting.

Article - Angiotensin receptor biased ligands and Acute Heart Failure

Beta-arrestin-biased ligands at the AT1R: a novel approach to the treatment of acute heart failure. Drug Discovery Today: Therapeutic Strategies.

Article - Molecular mechanisms of biased AT1R ligand pharmacology, a collaboration with J. Solaro

The β-arrestin-Biased Ligand TRV120023 Inhibits Angiotensin II-Induced Cardiac Hypertrophy While Preserving Enhanced Myofilament Response to Calcium

Poster - TRV027 Phase 2a hemodynamics study summary

TRV027, a β-arrestin biased ligand at the angiotensin 2 type 1 receptor, produces rapid, reversible changes in hemodynamics in patients with stable systolic heart failure. Presented at 2013 American College of Cardiology meeting

Article - Review of biased ligands in heart failure

GPCR biased ligands as novel heart failure therapeutics. Article in Press. Available online March 15th 2013

Poster - TRV027 Phase 1 FTIH study summary

First human dosing experience with TRV027, a novel therapy for acute heart failure. Presented at 2012 Heart Failure of America Society meeting

Article - Cardioprotective properties of biased AT1R ligands

β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol 303:H1001-H1010, 2012. First published 10 August 2012

Article - TRV027 in normal and heart failure canines, a collaboration with J. Burnett

Cardiorenal Actions of TRV120027, a Novel, β-Arrestin-Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines: A Novel Therapeutic Strategy for Acute Heart Failure. Circ Heart Fail. 2011 Aug. PubMed PMID: 21835984.

Article - Review of biased ligands for cardiovascular disease

Biased ligands for better cardiovascular drugs:dissecting G protein-coupled receptor pharmacology. Circ Res. 2011 Jul. PubMed PMID: 21737816.

Article - The discovery, in vitro profile, & rodent pharmacology of TRV027

Selectively engaging Beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010 Dec.

Poster - TRV027 in-vitro and in-vivo pharmacology summary

TRV120027, a Beta-arrestin biased ligand at the angiotensin II type 1 receptor, produces unique pharmacology and is a novel potential therapy for heart failure. Presented at the 2010 Heart Failure of Society of America meeting

Copyright © Trevena, Inc.